Wendy B. Young - 12 Jun 2026 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship: Director
Issuer ticker: ADIL
Reported as of: 12 Jun 2026
Net transaction value: +$99,999
SEC form: 4
Accepted by SEC: 16 Jun 2026, 06:14:30 UTC
Prior SEC filing: 16 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Davidson, Attorney-in-Fact

Key filing fact

Wendy B. Young filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 16 Jun 2026.

Key facts

This page summarizes Wendy B. Young's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2026, 06:14.

Change

Previous filing in this sequence was filed on 16 Jun 2026.
Current net transaction value: +$99,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002042847 Primary reporting owner

Young Wendy B.

Relationship: Director
Address: C/O ADIAL PHARMACEUTICALS, INC., 4870 SADLER ROAD, SUITE 300, GLEN ALLEN,
Signature: /s/ Matthew Davidson, Attorney-in-Fact
Signature date: 16 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Pre-funded Warrant

Purchase

Transaction value: $99,999
Shares: +36,378
Change %
Price: $2.75
Shares after: 36,378
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,378
Exercise price: $0.001000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the terms of that certain Pre-Funded Warrant to Purchase Common Stock, dated June 12, 2026, issued by the Issuer to the Reporting Person pursuant to a securities purchase agreement entered into by and among the Issuer, the Reporting Person and certain other parties on June 11, 2026.

Footnote F2

The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after receiving approval of the Issuer's stockholders. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.